MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica BROOMFIELD, Colo., April 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan product is now available in Santa Monica at Medical Imaging Center of Southern California (MICSC). Until now, MICSC has provided Nociscan exclusively at their Beverly Hills location. "We are

Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update on its strengthened positioning following the succ

BROOMFIELD, Colo., March 26, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Friday March 28, 2025, it will complete a 1-for-27 reverse stock split of its common stock. On September 23, 2024, the Company's stockholders approved an amendment to the Company's Certificate of Incorporation to affect a reverse stock split with the exact ratio to be set by its Board of Directors. The Board resolved to set the reverse stoc

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

NT 10-K - Aclarion, Inc. (0001635077) (Filer)

8-K - Aclarion, Inc. (0001635077) (Filer)

8-K - Aclarion, Inc. (0001635077) (Filer)

CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pa

Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

SC 13G - Aclarion, Inc. (0001635077) (Subject)

SC 13G/A - Aclarion, Inc. (0001635077) (Subject)